Xitong Ren

Chinese Academy of Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Zhaohui Tang

Chinese Academy of Sciences

Jiali Sun

Lanzhou Institute of Chemical Physics

Fuxin Xue

Union Hospital

Linjie Cui

Chinese Academy of Sciences

Haochen Yao

Jilin University

Na Shen

Chinese Academy of Sciences

Mengfei Zheng

Changchun Institute of Applied Chemistry

Linlin Liu

Shanghai Jiao Tong University

Junli Hu

Changchun Institute of Applied Chemistry

Kazuo Sakurai

The University of Kitakyushu

Cooperative Institutions

Changchun Institute of Applied Chemistry

Chinese Academy of Sciences

Jilin University

University of Science and Technology of China

First Hospital of Jilin University

Northeast Normal University

Jilin Medical University

Union Hospital

Chinese Academy of Medical Sciences & Peking Union Medical College

Nanjing Agricultural University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Polymeric PD1/PDL1 Bispecific Antibody Enhances Immune Checkpoint Blockade Therapy

Materials Today Bio (2024)

Fuxin Xue Xitong Ren Chaoying Kong Jianfeng Wang Linlin Liu

Immune checkpoint

Bispecific antibody

10.1016/j.mtbio.2024.101239

Cite

Citations (0)

ROS-responsive TLR7/8 nanoagonist and ultrasound modulate dendritic cells antigen presentation

Nano Today (2024)

Xitong Ren Haochen Yao Jiali Sun Fuxin Xue Linjie Cui

TLR7

Cross-Presentation

Presentation (obstetrics)

10.1016/j.nantod.2024.102402

Cite

Citations (2)

Poly(L-glutamic acid) based composites for improved dual immune checkpoint blockade therapy

Research Square (Research Square) (2024)

Fuxin Xue Haochen Yao Jiali Sun Xitong Ren Junli Hu

Abstract The immune checkpoint blockade (ICB) therapy, such as PD1/PDL1 blockade, is successful for robusting the duable response of patients. However, the response rate is less than 30%. In this study, we prepared polymer-Fc binding peptides-based PD1/PDL1 bispecific antibody (BsAb), which was constructed via the condensation reaction between side –COOH of poly( L -glutamic acid) (PGLU) and –NH 2 of a double cyclic peptide Fc-III-4C, and mixed with αPD1 and αPDL1 monoclonal antibodies (mAbs) in an aqueous solution. The PD1/PDL1 BsAb forms a bridge between tumor cells and CD8 + T cells, persistently activating the CD8 + T cell to a greater degree, and results in a much stronger inhiation of tumor growth and a longer survival time of mice in mouse colon cancer model, than both the free mAb and free mixed mAbs. The tumor suppression rate of the BsAb was 90.1% and after 48 days, the survival rate is 83.3%. Thus, this study highlights an effective PD1/PDL1 BsAb synchronizing T cell engager and dual ICBs, facilitating and guiding theoretically the clinical ICB therapy.

Immune checkpoint

10.21203/rs.3.rs-3940308/v1

Cite

Citations (0)

A tumor‐targeting nano‐adjuvant for in situ vaccine based on ultrasound therapy

Aggregate (2024)

Linjie Cui Haochen Yao Fuxin Xue Jiali Sun Xitong Ren

Abstract Ultrasound‐generated antigens combined with TLR7/8 agonists as adjuvants have demonstrated significant anti‐tumor efficacy as an in‐situ vaccine. However, the use of TLR7/8 agonists can cause severe inflammatory responses. In this study, we present a novel tumor‐targeting nano‐adjuvant termed aPDL1‐PLG/R848 NPs, which are composed of aPDL1 antibody, Fc‐III‐4C peptide linker (Fc‐linker) and poly( L ‐glutamic acid)‐ grafted ‐R848. Under ultrasound irradiation, antigen‐presenting cells activate immune mechanisms in vivo under dual stimulation of in situ antigens and immune adjuvants. The strategy inhibits primary tumor growth and induces a strong antigen‐specific immune memory effect to prevent tumor recurrence in vivo. This work offers a safe and potent platform for an in situ cancer vaccine based on ultrasound therapy.

Cancer vaccine

TLR7

Linker

10.1002/agt2.504

Cite

Citations (5)

Radiation-Activated Resiquimod Prodrug Nanomaterials for Enhancing Immune Checkpoint Inhibitor Therapy

Nano Letters (2024)

Jiali Sun Haochen Yao Xitong Ren Linjie Cui Linlin Liu

Immune checkpoint inhibitor (ICI) therapy is effectively employed in treating various malignancies. However, the response rate is constrained to 5–30%, which is attributed to differences in immune responses across different tumors. Overcoming all obstacles of multistep immune activation with monotherapy is difficult. Here, maleimide-modified resiquimod (R848) prodrug nanoparticles (MAL-NPs) are reported and combined with radiotherapy (RT) and anti-PD1 to enhance ICI therapy. MAL-NPs can promote antigen endocytosis by dendritic cells and are radio-reduced to produce R848. When combined with RT, MAL-NPs can augment the concentration of nanoparticles at tumor sites and be selectively radio-reduced within the tumor, thereby triggering a potent antitumor immune response. The systemic immune response and long-term memory efficacy induced by MAL-NPs + RT + anti-PD1 significantly inhibit the abscopal tumor growth and prevent tumor recurrence. This strategy can achieve systemic therapy through selective training of the tumor immune microenvironment, offering a new approach to overcome the obstacles of ICI therapy.

Abscopal effect

Immune checkpoint

10.1021/acs.nanolett.4c00114

Cite

Citations (5)

A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy

Chinese Journal of Polymer Science (2023)

Zhilin Liu Xitong Ren Yue Huang Jiali Sun Xiaoshuang Wang

10.1007/s10118-023-2921-7

Cite

Citations (4)